BRMS1 and prostate carcinoma: This fact suggests that these MREs could be amenableregulators for therapeutic targeting of metastaticbreast cells to express BRMS1. Our results confirmedthe results of other research groups who investigatedthe MRE-based strategy of gene therapy for severaltypes of malignancies including osteosarcoma (35),bladder cancer (36), uveal melanoma (37), lung (38)and prostate cancers (39).